Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
12/2003
12/04/2003WO2003099839A1 Modulators and inhibitors of fibroblast growth factor receptor 5_polypeptides and gene expression thereof.
12/04/2003WO2003099830A2 Cardiolipin compositions, methods of preparation and use
12/04/2003WO2003099781A2 METHODS FOR THE IDENTIFICATION OF IKKα FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
12/04/2003WO2003099341A1 Increased delivery of a nucleic acid constrtuct in vivo by the poly-l-glutamate (plg) system
12/04/2003WO2003099340A1 Novel chimeric cd154
12/04/2003WO2003099339A1 Decoy composition for treating and preventing inflammatory disease
12/04/2003WO2003099321A1 Methods for preventing, treating or delaying cardiac toxicity using neuregulin
12/04/2003WO2003099320A1 Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
12/04/2003WO2003099319A1 Preventive/remedy for arteriosclerosis
12/04/2003WO2003099318A2 Pancreas-specific proteins
12/04/2003WO2003099300A1 Neuregulin based methods and compositions for treating cardiovascular diseases
12/04/2003WO2003099225A2 Compositions for delivering nucleic acids to cells
12/04/2003WO2003099224A2 Antisense moodulation of kinesin-like 1 expression
12/04/2003WO2003099219A2 Bryostatins, bryopyrans and polyketides: compositions and methods
12/04/2003WO2003099215A2 Antisense modulation of glucocorticoid receptor expression
12/04/2003WO2003099213A2 Method for reducing platelet count
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099193A2 Vaccines
12/04/2003WO2003072771A3 Method of preparing a treatment product using a togaviridae expression construct
12/04/2003WO2003072727A3 EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
12/04/2003WO2003072703A3 Adenoviral vector with replication-dependent transgene expression
12/04/2003WO2003066810A3 Recombinant bovine immunodeficiency virus based gene transfer system
12/04/2003WO2003063785A3 Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
12/04/2003WO2003060096A3 Assay for the detection of factors that modulate the expression of ingap
12/04/2003WO2003059290A3 Diagnostic and therapeutic uses of topors
12/04/2003WO2003057898A8 Methods and materials for modulating p2x2
12/04/2003WO2003050281A3 Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity
12/04/2003WO2003048362A3 Suppression of polymeric alleles
12/04/2003WO2003048338A3 Nucleic acid injected into hepatic vein lumen and delivered to primate liver
12/04/2003WO2003046134A3 Expression of polypeptides in rod outer segment membranes
12/04/2003WO2003045415A3 Self-assembling p53 peptides as gene delivery vehicles
12/04/2003WO2003035010A3 Thymosin augmentation of genetic immunization
12/04/2003WO2003032920A3 Oligonucleotide modulation of cell adhesion
12/04/2003WO2003028537A3 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
12/04/2003WO2003025003A3 Hiv-gag codon-optimised dna vaccines
12/04/2003WO2003020901A3 Compositions and methods relating to prostate specific genes and proteins
12/04/2003WO2003018755A3 Wild-type ras as a cancer therapeutic agent
12/04/2003WO2003016560A3 Methods for diagnosing and treating neoplasias using nf-at transcription factors
12/04/2003WO2003014152A3 Phosphatidylinositol 5-phosphate-binding proteins
12/04/2003WO2003012059A3 Antisense modulation of cyclin d2 expression
12/04/2003WO2003012043A3 Enhancing organ maturity in neonates and predicting their duration of intensive care
12/04/2003WO2003008579A3 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002086134A3 Buffer solution for electroporation and a method comprising the use of the same
12/04/2003WO2002086090A3 Identification of essential genes of aspegillus fumigatus and methods of use
12/04/2003WO2002083892A3 Mutants of desoxycytidine kinase having extended enzymatic activity
12/04/2003WO2002082077A3 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
12/04/2003WO2002081510A3 Proteins, polynucleotides encoding them and methods of using the same
12/04/2003WO2002070708A3 Glutamate receptor modulatory proteins and nucleic acids encoding them
12/04/2003WO2002069840A3 Nucleic acids for transforming fish cells and methods for their use
12/04/2003WO2002068635A3 Methods of inhibiting expression of a target gene in mammalian cells
12/04/2003WO2002064827A3 Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof
12/04/2003WO2002043774A3 Compositions and therapeutical use of polynucleotides encoding tcrs
12/04/2003WO2002030462A3 Hedgehog antagonists, methods and uses related thereto
12/04/2003WO2001072771A3 Insulin and igf-1 receptor agonists and antagonists
12/04/2003US20030225023 Gene SHINC-2 and diagnostic and therapeutic uses thereof
12/04/2003US20030225022 Suppression of eIF5A1 expression to prevent retinal ganglion cell death in the glaucomatous eye
12/04/2003US20030225021 Methods of inducing the expression of bone morphogenetic proteins (BMPs) and transforming growth factor-beta proteins (TGF-betas) in cells
12/04/2003US20030225020 Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
12/04/2003US20030225012 Antisense modulation of transcription factor DP-1 expression
12/04/2003US20030225009 28 human secreted proteins
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224976 Compositions, methods and kits relating to behab and primary CNS tumors
12/04/2003US20030224968 Identifying subjects who have or are at risk for developing Hereditary Spastic Paraplegia by detecting the presence or absence of one or more variations in the atlastin gene or treating HSP by administering atlastin
12/04/2003US20030224522 Methods for delivering nucleic acid molecules into cells and assessment thereof
12/04/2003US20030224517 Comprises oligonucleotides which inhibit secretase activity on amyloid precursor proteins (APP) for treating alzheimer's and neurodegenerative diseases
12/04/2003US20030224512 Antisense modulation of beta-site APP-cleaving enzyme expression
12/04/2003US20030224511 Oligonucleotide for preventing cysteine protease expression (CAPTHESIN Z) and treatment of viral, infectious and tumor diseases
12/04/2003US20030224509 DAP-kinase and HOXA9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
12/04/2003US20030224508 Novel vectors and genes exhibiting increased expression
12/04/2003US20030224498 Comprises nucleotide sequences coding serpin domains for diagnosis and treatment of metabolic and infectious disorders; enzyme inhibitors; cosmetic or nutriceutical; drug screening
12/04/2003US20030224483 Control of gene expression in eukaryotic cells
12/04/2003US20030224414 Comprises nucleotide sequences coding enzymatic polypeptide for diagnosis, prognosis and treatment of cell proliferative disorders
12/04/2003US20030224413 Comprises polynucleotides coding restriction fragment length polymorphism for use in identifying, characterizing and treatment of blood, respiratory, tumor and nervous system disorders
12/04/2003US20030224402 Progression suppressed gene 13 (PSGen 13) and uses thereof
12/04/2003US20030224381 Delta-erythroid kruppel-like factors and methods of use
12/04/2003US20030224377 Novel LNA compositions and uses thereof
12/04/2003US20030224362 Diagnosing alcoholism using presence of mutation in neuropeptide y gene; drug abuse; restriction fragment length polymorphisms; immunoassay
12/04/2003US20030224355 Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (alpha), HNF-1beta and HNF-4alpha
12/04/2003US20030224354 Quantifying viral particles with intrinsic fluorescence
12/04/2003US20030224041 Emulsion formulations for hydrophilic active agents
12/04/2003US20030224040 Genomic screen for epigenetically silenced genes associated with cancer
12/04/2003US20030224018 Modified Vaccinia Virus Ankara for the vaccination of neonates
12/04/2003US20030224012 Identifying a BASB033 polypeptide or an antibody that is immunospecific for such polypeptide, present with in a biological sample form the animal suspected having meningococcus induced infections and meningitis
12/04/2003US20030224004 Chlamydia antigens and corresponding DNA fragments and uses thereof
12/04/2003US20030223990 A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers. 193P1E1 provides
12/04/2003US20030223980 Uses of thioredoxin
12/04/2003US20030223976 Control sequences of the human corin gene
12/04/2003US20030223975 Based on the discovery that a Y-box protein binding site is present as a transcription enhancer sequence in the promoter region situated upstream (i.e., 5' to) of the human PTP1B gene. This site, situated at nucleotides -155 through -132 of
12/04/2003US20030223973 Discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of
12/04/2003US20030223971 Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
12/04/2003US20030223970 Methods and compounds for prevention of graft rejection
12/04/2003US20030223967 Expression constructs encoding the tumor suppressor p53 for the prevention or treatment of vascular stenosis caused by vascular smooth muscle cell (VSMC) proliferation and/or migration in response to vascular trauma. This p53 therapy
12/04/2003US20030223966 Treatment for pompe disease
12/04/2003US20030223965 Bone generation by gene therapy
12/04/2003US20030223964 Efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the
12/04/2003US20030223963 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/04/2003US20030223962 Delivery of gene products to the lung parenchyma via gene transfer to the pleura
12/04/2003US20030223961 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
12/04/2003CA2493902A1 Decoy composition for treating and preventing inflammatory disease
1 ... 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 ... 870